• PROTACs Target Botulinum Neurotoxin Light Chains for Clearan

  2026-06-18

  This study pioneers the use of proteolysis-targeting chimeras (PROTACs) to selectively degrade botulinum neurotoxin light chains, offering a potential solution to both tune the persistence of engineered toxins and address iatrogenic botulism. The findings provide crucial mechanistic insights into leveraging the ubiquitin–proteasome system for targeted protein clearance.

• Biotin Azide (A8013): Precision Bio-Orthogonal Labeling Reag

  2026-06-18

  Biotin Azide enables high-specificity, bio-orthogonal labeling of alkynylated biomolecules via copper-catalyzed azide-alkyne cycloaddition. Its robust solubility and purity facilitate reproducible affinity purification and detection. APExBIO supplies Biotin-azide with validated performance for click chemistry workflows.

• A1 vs. AMD3100: Advancing CXCR4 Inhibition in Colorectal Can

  2026-06-17

  Khorramdelazad et al. present A1, a fluorinated CXCR4 inhibitor, as a novel agent with enhanced efficacy over AMD3100 in colorectal cancer models. Their integrated computational, in vitro, and in vivo analyses reveal A1's superior binding affinity, tumor inhibition, and immune modulation, suggesting a promising direction for targeted cancer therapies.

• Topotecan HCl: Potent Topoisomerase 1 Inhibitor for Cancer M

  2026-06-17

  Topotecan HCl is a semisynthetic camptothecin analogue and a highly specific topoisomerase 1 inhibitor. It induces DNA damage and apoptosis in rapidly dividing tumor cells, demonstrating robust antitumor activity in preclinical lung, colon, and prostate cancer models.

• Fludarabine: DNA Synthesis Inhibitor in Oncology Research Wo

  2026-06-16

  Fludarabine empowers translational cancer research by delivering reproducible DNA synthesis inhibition, robust apoptosis induction, and synergy with neoantigen-focused immunotherapies. Leverage its unique mechanism to optimize leukemia and multiple myeloma models, while troubleshooting common assay pitfalls with evidence-backed parameters.

• AEBSF.HCl: Advanced Protocols for Protease Inhibition and Am

  2026-06-16

  AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) empowers researchers to precisely control serine protease activity in complex models of cell death and neurodegeneration. This guide details optimized protocols, troubleshooting strategies, and new insights from recent necroptosis research to elevate experimental reproducibility and impact.

• Trichostatin A (TSA): Precision Tools for Breast Cancer Epig

  2026-06-15

  Explore how Trichostatin A (TSA) advances breast cancer research through targeted epigenetic regulation. This article uncovers TSA’s unique mechanistic roles, bridges assay design with molecular heterogeneity, and offers protocol guidance tailored to cutting-edge oncology.

• BOP Reagent in Peptide Synthesis: Precision, Protocols, and

  2026-06-15

  BOP reagent (benzotriazol-1-yloxy-tris(dimethylamino)phosphanium hexafluorophosphate) is a gold-standard tool for peptide bond formation, excelling in robust carboxyl group activation and phenyl ester preparation workflows. This article decodes its applied advantages, stepwise protocols, and strategic troubleshooting for translational oncology and advanced prodrug synthesis.

• Topotecan (SKF104864): Advanced Strategies for Glioma and Pe

  2026-06-14

  Explore Topotecan (SKF104864) as a cell-permeable topoisomerase inhibitor in glioma and pediatric solid tumor research. This article uniquely integrates mechanistic insights and protocol optimization, offering guidance beyond prior reviews.

• LY-411575: Gamma-Secretase Inhibitor for Alzheimer’s Workflo

  2026-06-13

  LY-411575, a potent gamma-secretase inhibitor, empowers researchers to dissect amyloid beta and Notch signaling with unmatched specificity. This guide translates advanced bench protocols and troubleshooting strategies using APExBIO’s LY-411575, maximizing its translational value in Alzheimer’s and cancer biology studies.

• Disrupting SARS-CoV-2 Nucleocapsid Condensation to Inhibit R

  2026-06-12

  The referenced study demonstrates that SARS-CoV-2 nucleocapsid protein undergoes RNA-driven liquid–liquid phase separation (LLPS), a process essential for viral assembly and replication. The natural polyphenol (-)-gallocatechin gallate (GCG) was found to disrupt this condensation, revealing a new antiviral mechanism and highlighting phase separation as a promising drug target.

• Allosteric Aptamer Biosensor Enables Live Tracking of Endoge

  2026-06-12

  This study introduces a genetically encoded allosteric biosensor (circStep) that enables direct, real-time visualization of endogenous protein localization and abundance in living cells without genetic perturbation. By integrating a protein-specific aptamer and dual-locked fluorogenic RNA aptamer modules, the approach achieves high specificity and minimal background, advancing high-throughput protein dynamics research and drug screening.

• AR Heterogeneity and Distinct Drug Responses in Prostate Can

  2026-06-11

  This study uncovers how heterogeneous androgen receptor (AR) expression in prostate cancer underpins divergent responses to castration and enzalutamide therapies. The findings reveal BCL-2 as a critical vulnerability in AR-low/negative castration-resistant prostate cancer (CRPC), guiding new combinatorial treatment strategies.

• Oscillatory mTORC1 Activity Coordinates Cell Cycle and Autop

  2026-06-11

  Joshi et al. reveal that mTORC1 activity oscillates across the cell cycle, peaking in S/G2 and reaching its lowest in mitosis and G1. This dynamic regulation is crucial for mitotic entry and phase-specific autophagy sensitivity, providing new mechanistic insight for cell cycle and metabolic research.

• IWR-1-endo: Precision Wnt Pathway Inhibition for Next-Gen As

  2026-06-10

  Explore how IWR-1-endo, a potent Wnt signaling inhibitor, advances experimental reproducibility and pathway specificity in disease modeling. This article reveals fresh insights into assay design and mechanistic nuances, setting it apart from prior coverage.

15896 records 1/1060 page Next 12345 下5页 Last page